source
- Eli Lilly Q2 revenue hits $23 billion, topping forecasts as tirzepatide drives two-thirds of salesEli Lilly reported second-quarter revenue of $23 billion, roughly $3 billion above analysts' estimates. Tirzepatide contributed about 64% of the total, highlighting its central role in the company…
- FDA approves Takeda's orexin drug for narcolepsy type 1Takeda has received FDA approval for its orexin agonist intended to treat narcolepsy type 1. The decision ends a closely watched commercial race to bring an orexin-based therapy to market. With a…